Trial Profile
Multicentre Study to Assess the Effect of Prophylactic Antipyretic Treatment on the Rate of Febrile Reactions Following Concomitant Administration of GSK Biologicals' 10-valent Pneumococcal Conjugate, Infanrix Hexa and Rotarix Vaccines
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Paracetamol; RIX 4414
- Indications Diphtheria; Fever; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
- Focus Therapeutic Use
- Acronyms 10PN-PD-DIT-010
- Sponsors GlaxoSmithKline; GSK
- 30 May 2013 Planned number of patients changed from 750 to 400 as reported by ClinicalTrials.gov.
- 03 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2009 Results of primary and booster vaccination published in the Lancet.